MHRA Approves Zuranolone for Postnatal Depression Treatment in Adults

The UK's MHRA has approved zuranolone to treat postnatal depression in adults following childbirth. Biogen Inc., a leading therapeutic products manufacturer, generates 74.6% of its net sales from medicine sales, 6.7% from royalties, and 18.7% from other sources, primarily partnership agreements.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Biogen Inc.'s (BIIB) Zuranolone to treat moderate or severe postnatal depression in adults following childbirth. This marks a significant milestone in the treatment of postnatal depression, which affects many parents after having a baby. Zuranolone is the first oral treatment for postnatal depression approved in the UK, according to the MHRA [2].

Biogen Inc., a global leader in therapeutic products, generates 74.6% of its net sales from the sale of medicines, 6.7% from royalties, and 18.7% from other sources, primarily partnership agreements [1]. This approval could potentially boost Biogen's revenue streams, given the company's strong focus on medicine sales.

Zuranolone is administered as a capsule taken orally at night with a fat-containing meal for 14 days. The approval comes after successful clinical trials, which demonstrated the drug's efficacy in managing postnatal depression symptoms.

This development underscores Biogen's commitment to developing innovative treatments for various health conditions. The company's diverse revenue streams, including partnerships and royalties, provide a stable foundation for continued research and development.

References:
[1] https://www.marketscreener.com/news/biogen-s-postnatal-depression-drug-zuranolone-gets-uk-approval-ce7c50ded189f721
[2] https://stocktwits.com/news-articles/markets/equity/uk-regulator-approves-biogen-drug-for-treating-postnatal-depression/chsUel3Rdl9